A 4-week, randomized, double-blind, cohort study to evaluate the safety and tolerability of converting from ropinirole immediate release (IR) to ropinirole extended release (XR) formulation in patients with restless legs syndrome (RLS)

Trial Profile

A 4-week, randomized, double-blind, cohort study to evaluate the safety and tolerability of converting from ropinirole immediate release (IR) to ropinirole extended release (XR) formulation in patients with restless legs syndrome (RLS)

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Sep 2016

At a glance

  • Drugs Ropinirole (Primary)
  • Indications Restless legs syndrome
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Nov 2006 Status change
    • 18 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top